PF-Atlas › Clinical Trials › NCT06572384
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Belimumab · Phase 3
Registry ID
NCT06572384
Phase
Phase 3
Status
Recruiting
Drug / intervention
Belimumab
Sponsor
GlaxoSmithKline
Start
2024-09-11
Enrollment
440
Locations
131
About this trial
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT06572384 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.